Biggest News Aggregation in the World
📰 Synact Pharma News

Page 2 - Synact Pharma News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Synact Pharma. Real-time updates on events, politics, business and more.

SynAct Pharma AB announces positive data from a Phase 2a trial of AP1189 in Covid-19 infected patients - The William Harvey Research Institute

SynAct Pharma AB announces positive data from a Phase 2a trial of AP1189 in Covid-19 infected patients SynAct Pharma AB (“SynAct”) has just announced topline results from the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency.  Patients treated with 100mg AP1189 orally once-daily for 2-weeks achieved respiratory recovery (time to normalization of oxygen saturation on ambient air) on average 3.5 days (35%) quicker than placebo treated patients (6.4...
United Kingdom City Of Mauro Teixeira Synact Pharma Mauro Perretti Phd William Harvey Research Institute
Source: qmul.ac.uk

SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients

Sponsrat Sponsrat SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients SynAct Pharma AB ("SynAct") today announced that dosing in part 2 of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been completed. The study is a randomized double-blind placebo-controlled study in 54 Covid-19 patients at clinical sites at Universidade Fede...
United Kingdom City Of Synact Pharma Mauro Perretti Mauro Teixeira Belo Horizonte
Source: realtid.se

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

SynAct Pharma partners with Örebro University to study cardiovascular disease

SynAct Pharma partners with Örebro University to study cardiovascular disease Publicerad: 12 maj 2021 13:37 Uppdaterad: 12 maj 2021 13:37 SynAct Pharma AB ("SynAct") today announced the company is a partner in a research project at Örebro University to study the reduction of inflammation in vascular disease. Dela på Facebook Uppdaterad: 12 maj 2021 13:37 The study, named “Targeting the melanocortin system as a novel strategy to reduce inflammation during vascular disease,” will ...
Liza Ljungberg Thomas Jonassen Synact Pharma Knowledge Foundation School Of Medical Sciences Senior Lecturer Liza Ljungberg
Source: breakit.se

SynAct Pharma: Interim report January-March 2021

The Groups profit before tax amounted to -14,070 ( -3,822) TSEK. The Groups earnings per share amounted to -0.46 (-0.14). The average number of shares for the period was 25,366,295. "SynAct Pharma AB" means the parent company SynAct Pharma AB with corporate registration number 559058-4826. The "Company" or "SynAct" means the Group, i.e. SynAct Pharma AB and its wholly owned subsidiary SynAct Pharma ApS. definitions Earnings per share: Profit for the period divided by the average number of shar...
Synact Thomas Boesen James Knight Thomas Jonassen Marina Bozilenko European Patent Office Company Or Synact
Source: realtid.se

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version Lund, Sweden, May 4, 2021. SynAct Pharma AB ("SynAct") today announced that based upon the encouraging results seen in part 1 of the phase 2 clinical study BEGIN of AP1189, the company has decided to increase the study size in an effort to demonstrate statistical significance in the trial. SynAct Publicerad: 4 maj 2021, 08:00 Topline data from part 1 of the BEGIN study with AP1189 in early rheumatoid arthristis (RA) dem...
San Francisco United States Thomas Jonassen Synact Pharma American College Of Rheumatology Data Safety Monitoring Board
Source: di.se

SynAct Pharma Board and Management extend lock-up period   UK Version

SynAct Pharma Board and Management extend lock-up period   UK Version SynAct Pharma AB ("SynAct") today announced all members of its board and management team have extended the lock-up period for their SynAct Pharma shares until December 31, 2021. In total the lock-up agreements correspond to more than 20 percent of the votes and capital in SynAct Pharma. Uppdaterad 2021-05-04 Publicerad 2021-05-04 “The members of the board and the entir...
Synact Pharma
Source: realtid.se

SynAct Pharma shareholders propose Marina Bozilenko as new board member

SynAct Pharma shareholders propose Marina Bozilenko as new board member SynAct Pharma AB ("SynAct") today announced that shareholders representing more than 20 per cent of the shares and votes in the company propose Marina Bozilenko to be elected as new board member of SynAct Pharma at the next annual general meeting set for May 21, 2021. Uppdaterad 2021-04-19 Publicerad 2021-04-19 Marina Bozilenko has more than 30 years of experience in in...
United States Synact Pharma Marina Bozilenko Acelrx Pharmaceuticals Vector Securities International University Of Chicago
Source: realtid.se

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science